PATIENT REPORTED OUTCOMES-CORE SHARED RESOURCE The Patient Reported Outcomes-Core Shared Resource (PRO-core) was developed in response to a growing number of cancer center investigators who require methodological consulting related to survey development, use, and analysis, as well as use of a customizable electronic data capture tool for collecting information directly from patients and other stakeholders. PRO Core provides a software platform and scientific consultation to investigators conducting PRO research. This includes clinical trials of new drugs, interventions with symptom and quality of life endpoints, and studies of the integration of PRO assessment into clinical care. Dr. Bennett is the faculty director and an Associate Professor of Health Policy and Management. She contributed as an investigator to the development and validation of the NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). In fiscal year 2019, the SR was used by 27 faculty, 67% of whom were LCCC members. Importantly, the SR supports highly sophisticated methodology and is a national leader in Patient Reported Outcomes. These skills and methods allow the SR to support external cancer collaborators at multi-site trial locations such as Duke Cancer Institute, Emory University, Georgetown, and Moffit. PRO is requesting $111,249 for this SR which is approximately 39% of its fiscal year 2020 Operating budget. PRO Core has been a successful SR as demonstrated by the following metrics. PRO Core studies are supported by 11 NIH grants (5 from NCI, including 1 K award) and 3 Patient-Centered Outcomes Research Institute (PCORI) contracts. Studies are also supported by Genentech, the Breast Cancer Research Foundation, and pilot awards from the Alliance for Clinical Trials in Oncology cooperative group. PRO Core is supporting a growing portfolio of: 1) studies evaluating the implementation of PRO assessment in oncology care, and 2) studies collecting both PRO data and wearable / activity tracker (e.g. Garmin, Fitbit) data. PRO Core has developed technical capability and expertise in these areas, and the LCCC is now known for substantial scientific leadership in these two areas. In addition, PRO Core is supporting studies that evaluate the comparative effectiveness of new treatments and a new registry that tracks opioid need and use among post-operative patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089834
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Smith, Jennifer S; Des Marais, Andrea C; Deal, Allison M et al. (2018) Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm Dis 45:42-48
Morris, Michael J; Rumble, R Bryan; Basch, Ethan et al. (2018) Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1521-1539
Hisada, Yohei; Thålin, Charlotte; Lundström, Staffan et al. (2018) Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res 165:1-5
Westmoreland, Katherine D; El-Mallawany, Nader K; Kazembe, Peter et al. (2018) Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. Br J Haematol 181:853-854
Kulis, Michael; Yue, Xiaohong; Guo, Rishu et al. (2018) High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children. Clin Exp Allergy :
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Lund, Jennifer L; Sanoff, Hanna K; Peacock Hinton, Sharon et al. (2018) Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiol Biomarkers Prev 27:41-49
Wu, Shih-Ying; Fix, Samantha M; Arena, Christopher B et al. (2018) Focused ultrasound-facilitated brain drug delivery using optimized nanodroplets: vaporization efficiency dictates large molecular delivery. Phys Med Biol 63:035002
Juliano, Rudolph L; Wang, Ling; Tavares, Francis et al. (2018) Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides. Nucleic Acids Res 46:1601-1613
El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7

Showing the most recent 10 out of 1525 publications